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analysis. The results correctly predicted the effect on sur-
vival due to increased age (negative), condition severity
(negative), complexity of drug therapy (positive), aggres-
sive drug therapy (positive), and a number of life-threat-
ening comorbid conditions (negative); the two inotrope
cohorts indicate a significant difference in in-hospital sur-
vival. Milrinone patients were more than twice as likely
to survive the in-hospital stay than dobutamine patients.
Further, dobutamine patients were twice as likely to sur-
vive than amrinone patients.
CONCLUSION: In-hospital survival varied significantly
by inotropic study cohort. Patients on milrinone had a
higher likelihood of survival.
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Addition of pravastatin to dietary advice has been shown
by the West of Scotland Coronary Prevention Study
(WOSCOPS) to prevent the transition from health to car-
diovascular disease.
METHODS: An economic analysis was conducted to as-
sess the cost-effectiveness of primary prevention with
pravastatin. Appropriate Canadian risk factor data were
used in an exponential regression model derived from
WOSCOPS data to estimate the rates at which Canadians
transition to cardiovascular disease. The number of tran-
sitions avoided were valued in terms of cost savings to the
Canadian health care system, as well as life years gained.
Canadian costs (1996 CAD $1 = $0.72 US) were based
on ICD-9-CM Ontario Case Cost Project inpatient hospi-
tal data and were discounted at 5% per annum beyond
the first year. The difference between age and gender-
specific Canadian life table survival and post-event sur-
vival obtained from Scottish linkage data was calculated
to estimate life years gained.
RESULTS: The prevention of 303 transitions to CVD,
which implies 3,067 years of life gained, would be
achieved if 10,000 Canadian hypercholesterolaemic men
started treatment. Based on these results, cost-effective-
ness ratios of $10,113ILYG (undiscounted) and $24,223/
LYG (discounted) were obtained. If only high-risk pa-
tients (defined by published consensus statements) are
treated, the ratios drop to between $6,865 and $16,391.
CONCLUSION: In light of published Canadian eco-
nomic analysis guidelines, this constitutes strong evidence
for adoption of primary prevention with pravastatin to
avoid the clinical manifestations of CVD.
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OBJECTIVE: The purpose of this study was to test the
hypothesis that patients with evidence of left-systolic ven-
tricular dysfunction treated with torsemide would have
fewer hospitalizations for heart failure, improved disease-
specific quality of life, and lower direct inpatient costs
compared to patients treated with furosemide. Pharmaco-
kinetic studies have shown that the bioavailability of
torsemide is more complete and predictable than furo-
semide, especially in patients with heart failure.
METHODS: Prospective, randomized trial. This is an in-
terim analysis of 191 hospitalized patients (65 years of
age::':: 12 SD) who were prescribed torsemide (n = 93) or
furosemide (n = 98) for 1 year. Data were analyzed at 15
months as part of a planned interim intention to treat
analysis. Duration of follow-up did not differ between
treatment groups (233 days::':: 134 SD). Dependent vari-
ables were the numbers of subsequent hospitalizations for
heart failure, other cardiovascular causes, and all causes,
their corresponding count of hospital days, and direct
costs. Disease-specific quality of life was measured using
the Chronic Heart Failure Questionnaire.
RESULTS: Patients treated with torsemide had signifi-
cantly fewer hospitalizations for heart failure (11 vs. 28)
and other cardiovascular causes (20 vs. 48). The differ-
ence in all cause hospitalizations was not significant (77
vs. 107). Hospital days were significantly less for patients
treated with torsemide for all cardiovascular causes only
(91 vs. 222) (p < 0.05). Dyspnea, fatigue, and total dis-
ease-specific quality of life were significantly better for
patients treated with torsemide. Direct inpatient costs for
all cause hospitalizations were $793,460 ($8,532 per pa-
tient) for torsemide and $1,161,617 ($11,617 per pa-
tient) for furosemide.
CONCLUSION: Patients treated with torsemide have
fewer hospitalizations for heart failure and other cardio-
vascular causes, improved dyspnea and fatigue, and
lower direct inpatient health care costs. These effects are
presumably due to the complete and reliable absorption
of torsemide.
